5.4.99.47	F124L/F365L/I732A	site-directed mutagenesis, the mutant shows reduced parkeol synthesis activity compared to the wild-type and synthesis of other triterpene products	-, 748774	
5.4.99.47	H477N	the mutant produces 88% lanosterol and 12% parkeol from oxidosqualene	653405	
5.4.99.47	H477Q	the mutant produces 73% parkeol, 22% lanosterol, and 5% DELTA7-lanosterol from oxidosqualene	653405	
5.4.99.47	Q450H	nonviable single mutant produces minor amount achilleol A as the sole product	728425	
5.4.99.47	Q450H/V454I	mutant produces lanosterol, (13alphaH)-isomalabarica-14(26),17E,21-trien-3 beta-ol, protosta-16,24-dien-3beta-ol in a ratio of 75:16:9	728425	
5.4.99.47	T384Y	mutant produces lanosterol, parkeol, 9beta-lanosta-7,24-dien-3 beta-ol, protosta-13(17),24-dien-3beta-ol and protosta-16,24-dien-3beta-ol in the ratio of 63:31.5:3.5:1:1 without compounds achilleol A and (13alphaH)-isomalabarica-14(26),17E,21-trien-3 beta-ol	728425	
5.4.99.47	T384Y/Q450H	mutant produces lanosterol, parkeol, 9 beta -lanosta-7,24-dien-3 beta-ol in a ratio of 1:98:1	728425	
5.4.99.47	T384Y/Q450H/V454I	mutant generates parkeol as the sole product, Vmax/Km 18fold decreased for 3S-2,3-oxidosqualene compared to wild-type	728425	
5.4.99.47	T384Y/V454I	mutant produces lanosterol, parkeol, 9 beta -lanosta-7,24-dien-3 beta-ol in a ratio of 10:84:6	728425	
5.4.99.47	V454I	mutant produces poor amounts of lanosterol and (13alphaH)-isomalabarica-14(26),17E,21-trien-3 beta-ol (ratio 90:10)	728425	
5.4.99.47	Y257A	site-directed mutagenesis, the mutant shows highly reduced parkeol synthesis activity compared to the wild-type	-, 748774